目的：观察逍遥散联合妥布霉素地塞米松治疗睑板腺功能障碍(MGD)性干眼症的临床疗效。

方法：选取2015-11/2017-11就诊于南阳市卧龙区第一人民医院的睑板腺功能障碍性干眼症患者106例134眼，随机分为对照组和观察组，各53例67眼。两组均给予热敷、按摩等基础治疗，对照组给予妥布霉素地塞米松治疗，观察组在对照组基础上联合逍遥散治疗。观察两组患者的临床疗效及治疗前后干眼症症状、角膜荧光染色(FL)、视功能损害眼病患者生活质量量表(SQOL DVI)评分、泪膜破裂时间(BUT)和泪液分泌量(SⅠt)等情况。

结果：治疗后，观察组患者治疗总有效率(86.6%)显著高于对照组(67.2%)，干眼症症状、角膜FL评分均显著低于对照组，BUT和SⅠt值及SQOL DVI评分均显著高于对照组，差异均有统计学意义(P<0.01)。治疗期间，观察组眼压升高发生率显著低于对照组，差异有统计学意义(P<0.05)。

结论：逍遥散联合妥布霉素地塞米松治疗睑板腺功能障碍性干眼症，能够显著提高疗效，改善预后情况。

METHODS: Totally 134 eyes of 106 dry eye patients with MGD in the First People's Hospital of Wolong District, Nanyang City from November 2015 to November 2017. They were randomly divided into the control group and the observation group, each with 53 cases(67 eyes). The two groups were all given hot compress massage, and other basic treatment. The control group was given tobramycin dexamethasone treatment, while the observation group was treated with Xiaoyao Powder on the basis of the control group. The clinical effect of two groups of patients, the symptoms of dry eye, corneal fluorescence staining(FL), the scale of quality of life for diseases with visual impairment(SQOL DVI), tear film break-up time(BUT)and the Schirmer test(SⅠT)were observed.

RESULTS: After treatment, the total effective rate of treatment in the observation group(86.6%)was significantly higher than that of the control group(67.2%). The symptoms of dry eye, corneal FL and SQOL DVI scores were significantly lower than those in the control group, and the values of BUT and SⅠT were significantly higher than those in the control group, the difference was statistically significant(P<0.01). During the treatment period, the incidence of intraocular pressure elevation in the observation group was significantly lower than that in the control group, the difference was statistically significant(P<0.05).

CONCLUSION: The Xiaoyao Powder combined with tobramycin dexamethasone in the treatment of MGD dry eye can significantly improve the curative effect and improve the prognosis of the patients.